We present the case of a 78-year-old African American man with a history of human immunodeficiency virus diagnosed in 2007 who was newly diagnosed with pancreatic cancer. A percutaneous endoscopic gastrostomy tube was placed during the initial inpatient visit of pancreatic cancer diagnosis due to persistent dysphagia. Due to PEG placement and the patient’s wish to continue his previous antiretroviral therapy, the patient crushed his fixed-dose bictegravir/emtricitabine/tenofovir alafenamide under the direction of a physician and has maintained virologic suppression.
TurleySLFulcoPP. Enteral administration of twice-daily dolutegravir and rilpivirine as a part of a triple-therapy regimen in a critically Ill patient with HIV. J Int Assoc Provid AIDS Care2017; 16(2): 117–119, Epub 2017 Feb 15. DOI: 10.1177/2325957417692678.
3.
BrooksKMGarrettKLKuriakoseSS, et al.Decreased absorption of dolutegravir and tenofovir disoproxil fumarate, but not emtricitabine, in an hiv-infected patient following oral and jejunostomy-tube administration. Pharmacotherapy2017; 37(8): e82–e89. DOI: 10.1002/phar.1960
4.
BuscemiL. Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection. Am J Health Syst Pharm2016; 73(15): 1125–1126. DOI: 10.2146/ajhp160102.
5.
MooreSEHuesgenEHoweZ. Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis. Int J STD AIDS2020; 31(3): 285–287, Epub 2020 Feb 9. DOI: 10.1177/0956462419895690
KaplunOPsevdosG. Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Am J Health Syst Pharm2019; 76(16): 1180–1181. DOI: 10.1093/ajhp/zxz132
8.
FulcoPP. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. Am J Health Syst Pharm2020; 77(7): 509–510. DOI: 10.1093/ajhp/zxaa017.
9.
LozanoABChuecaNde SalazarA, et al.Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. Antivir Res2020; 179: 104717, Epub 2020 Jan 23. DOI: 10.1016/j.antiviral.2020.104717
